| |
Number of patients (% in brackets)
| |
|---|
|
Demographic characteristics
|
Total population number (%)
|
PIK3CA WT, n(%)
|
PIK3CA mutation, n(%)
|
P-valueb
|
|---|
|
Totals
|
85 (100)
|
60 (70.6)
|
25 (29.4)
| |
|
Mean age (±SD), yr
|
70.9 (8.5)
|
71.0 (8.4)
|
70.7 (9.0)
| |
|
Histological grade
|
0.033
|
|
Number available
|
70
|
47
|
23
| |
|
1
|
13 (18.6)
|
5 (10.6)
|
8 (34.8)
| |
|
2
|
43 (61.4)
|
30 (63.8)
|
13 (56.5)
| |
|
3
|
14 (20.0)
|
12 (25.5)
|
2 (8.7)
| |
|
Unknown
|
15
| | | |
|
Stage (n = 85)
| | |
0.780
|
|
2
|
48 (56.5)
|
33 (55.0)
|
15 (60.0)
| |
|
3
|
28 (32.9)
|
21 (35.0)
|
7 (28.0)
| |
|
4
|
9 (10.6)
|
6 (10.0)
|
3 (12.0)
| |
|
Lymph nodes (n = 85)
| | |
0.472
|
|
Positive
|
35 (41.2)
|
23 (38.3)
|
12 (48.0)
| |
|
Negative
|
50 (58.8)
|
37 (61.7)
|
13 (52.0)
| |
|
Tumour sizec (n = 76)
| | |
0.610
|
|
T2
|
48 (63.2)
|
33 (61.1)
|
15 (68.2)
| |
|
T3
|
28 (36.8)
|
21 (38.9)
|
7 (31.2)
| |
|
Histology
| | | |
0.725
|
|
Number available
|
58
|
38
|
20
| |
|
Ductal
|
44 (75.9)
|
29 (76.3)
|
15 (75)
| |
|
Lobular
|
8 (13.8)
|
6 (15.8)
|
2 (10)
| |
|
Other
|
6 (10.3)
|
3 (7.9)
|
3 (15)
| |
|
Unknown
|
27
| | | |
|
ERα status
| | |
1.000
|
|
Number available
|
83
|
25
|
58
| |
|
Negative
|
0
|
0
|
0
| |
|
Positive
|
83 (100)
|
25 (100)
|
58 (100)
| |
|
Unknown
|
2
| | | |
|
PgR status
| | | |
0.49
|
|
Number available
|
83
|
58
|
25
| |
|
Negative
|
11 (12.9)
|
9 (15.5)
|
2 (8)
| |
|
Positive
|
72 (86.7)
|
49 (84.5)
|
23 (92)
| |
|
Unknown
|
2
| | | |
|
HER2 status
| | | |
1.000
|
|
Number available
|
82
|
57
|
25
| |
|
Negative
|
69 (84.1)
|
48 (84.2)
|
21 (84)
| |
|
Positive
|
13 (15.9)
|
9 (15.8)
|
4 (16)
| |
|
Unknown
|
3
| | | |
|
Subtype
| | | |
0.039
|
|
Number available
|
46
|
23
|
13
| |
|
Luminal A
|
22 (47.8)
|
11 (47.8)
|
11 (84.6)
| |
|
Luminal B
|
24 (52.2)
|
12 (52.2)
|
2 (15.4)
| |
- aER, Oestrogen receptor; HER2, Human epidermal growth factor receptor 2; PgR, Progesterone receptor; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α; WT, Wild type. bFisher’s exact test. P-value relates to the comparison between wild type and mutation. cMeasurements of tumour size were taken by caliper (n = 45), magnetic resonance imaging (n = 2), physical examination (n = 25) or ultrasound (n = 4). T4 and T4a patients (n = 1 and n = 8, respectively) were excluded from the analysis of tumour size.
